Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72


Outcomes of third-line docetaxel-based chemotherapy in advanced gastric cancer who failed previous oxaliplatin-based and irinotecan-based chemotherapies.

Lee MJ, Hwang IG, Jang JS, Choi JH, Park BB, Chang MH, Kim ST, Park SH, Kang MH, Kang JH.

Cancer Res Treat. 2012 Dec;44(4):235-41. doi: 10.4143/crt.2012.44.4.235. Epub 2012 Dec 31.


Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.

Jo JC, Lee JL, Ryu MH, Sym SJ, Lee SS, Chang HM, Kim TW, Lee JS, Kang YK.

Jpn J Clin Oncol. 2007 Dec;37(12):936-41. doi: 10.1093/jjco/hym123.


A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.

Choi YH, Oh SC, Kim JS, Nam SH, Kim BS, Cho SH, Chung IJ, Song EK, Yim CY, Baek JH, Jeung HC, Hong YS, Yang SH, Kang HJ.

Cancer Chemother Pharmacol. 2012 Nov;70(5):665-72. doi: 10.1007/s00280-012-1956-1. Epub 2012 Aug 25.


A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.

Lee JL, Ryu MH, Chang HM, Kim TW, Yook JH, Oh ST, Kim BS, Kim M, Chun YJ, Lee JS, Kang YK.

Cancer Chemother Pharmacol. 2008 Apr;61(4):631-7. Epub 2007 May 23.


Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer.

Zhong H, Zhang Y, Ma S, Ying JE, Yang Y, Yong D, Hang X, Sun Q, Zhong B, Wang D.

Anticancer Drugs. 2008 Nov;19(10):1013-8. doi: 10.1097/CAD.0b013e328314b5ab.


Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.

Kim JA, Lee J, Han B, Park SH, Park JO, Park YS, Lim HY, Kang WK.

Cancer Chemother Pharmacol. 2011 Jul;68(1):177-84. doi: 10.1007/s00280-010-1452-4. Epub 2010 Sep 28.


A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status.

Im CK, Rha SY, Jeung HC, Jeong J, Lee SH, Noh SH, Roh JK, Chung HC.

Oncology. 2009;77(6):349-57. doi: 10.1159/000265941. Epub 2009 Dec 14.


Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.

Heck MM, Thalgott M, Retz M, Wolf P, Maurer T, Nawroth R, Hatzichristodoulou G, Gschwend JE, K├╝bler H.

BJU Int. 2012 Dec;110(11 Pt B):E635-40. doi: 10.1111/j.1464-410X.2012.11364.x. Epub 2012 Aug 13.


Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.

Sym SJ, Ryu MH, Kang HJ, Lee SS, Chang HM, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang YK.

Cancer Chemother Pharmacol. 2010 Jul;66(2):373-80. doi: 10.1007/s00280-009-1171-x. Epub 2009 Nov 21.


Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.

Koizumi W, Akiya T, Sato A, Yamaguchi K, Sakuyama T, Nakayama N, Tanabe S, Higuchi K, Sasaki T, Sekikawa T; Tokyo Cooperative Oncology Group (TCOG GI Group).

Jpn J Clin Oncol. 2009 Nov;39(11):713-9. doi: 10.1093/jjco/hyp099. Epub 2009 Oct 6.


Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.

Seo HY, Kim DS, Choi YS, Sung HJ, Park KH, Choi IK, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS.

Cancer Chemother Pharmacol. 2009 Feb;63(3):433-9. doi: 10.1007/s00280-008-0753-3. Epub 2008 Apr 9.


Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.

Comella P, Natale D, Farris A, Gambardella A, Maiorino L, Massidda B, Casaretti R, Tafuto S, Lorusso V, Leo S, Cannone M.

Cancer. 2005 Jul 15;104(2):282-9.


The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Chauchereau A, Fizazi K.

Eur J Cancer. 2010 Jul;46(10):1770-2. doi: 10.1016/j.ejca.2010.04.010. Epub 2010 May 17.


Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer.

Kim YS, Hong J, Sym SJ, Park SH, Park J, Cho EK, Lee JH, Shin DB.

Cancer Res Treat. 2010 Mar;42(1):24-9. doi: 10.4143/crt.2010.42.1.24. Epub 2010 Mar 31.


Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.

Polyzos A, Felekouras E, Karatzas T, Griniatsos J, Dimitroulis D, Polyzos K, Kontzoglou K, Mantas D, Karavokyros J, Nikiteas N, Tsavaris N, Syrigos K, Vafiadis I.

Anticancer Res. 2012 Sep;32(9):4151-6.


Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status.

Chen YM, Shih JF, Fan WC, Wu CH, Chou KT, Tsai CM, Lee YC, Perng RP, Whang-Peng J.

J Chin Med Assoc. 2011 May;74(5):209-14. doi: 10.1016/j.jcma.2011.03.005. Epub 2011 Apr 9.


Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.

Kwon JH, Kim JH, Lee JA, Shin HC, Kim HJ, Song HH, Jung JY, Kim HY, Choi DR, Kim HS, Park YI, Zang DY.

Cancer Chemother Pharmacol. 2010 Oct;66(5):889-97. doi: 10.1007/s00280-009-1235-y. Epub 2010 Jan 21.


Capecitabine for the treatment of advanced gastric cancer.

Norman G, Soares M, Peura P, Rice S, Suh D, Wright K, Sculpher M, Eastwood A.

Health Technol Assess. 2010 Oct;14(Suppl. 2):11-7. doi: 10.3310/hta14suppl2/02. Review.


Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.

Cui Y, Li Q, Yu Y, Chen Y, Feng Y, Wang Y, Liu T.

Cancer Chemother Pharmacol. 2013 Jan;71(1):145-52. doi: 10.1007/s00280-012-1991-y. Epub 2012 Oct 12.


Supplemental Content

Support Center